Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Preferred Stock Liabilities (2022 - 2023)

Historic Preferred Stock Liabilities for Standard Biotools (LAB) over the last 3 years, with Q4 2023 value amounting to $311.3 million.

  • Standard Biotools' Preferred Stock Liabilities changed 0.0% to $311.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $311.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $311.3 million for FY2023, which is 0.0% changed from last year.
  • Latest data reveals that Standard Biotools reported Preferred Stock Liabilities of $311.3 million as of Q4 2023, which was down 0.0% from $311.3 million recorded in Q3 2023.
  • Standard Biotools' 5-year Preferred Stock Liabilities high stood at $311.3 million for Q2 2022, and its period low was $311.3 million during Q2 2022.